ASCO Update #2: Stock Performance Data as of 6/8/17

http://tomcarter.co.uk/art-documentation/galleries/arcadia-missa/ ASCO Update: Many Stocks Rallied on the News Over the Past Month

buy Lyrica online overnight ASCO Rally is Holding but Fails to Break Through to New 2017 Highs

The stock performance of most companies with ASCO news is summarized below.Biotechnology stocks are driven by clinical and deal news so here are some trends to consider:

In our next review of ASCO related stocks we will look through the data to identify breakthrough product potential and upgrades.

Company Ticker Price Perform Perform MarkCap
6/8/17 YTD 30 days $B
$ % %
Agios Pharma AGIO 50.3 20.9 2.98 2.5
bluebird bio BLUE 111 79.9 25 5.05
Bristol MyersSquibb BMY 52.77 -9.57 -3.8 88.6
Celgene CELG 117.07 1.13 -1.1 91.9
Clovis Oncology CLVS 59.1 34 24.9 2.76
Epizyme EPZM 11.4 -5.37 -24.7 0.626
Exelixis EXEL 19.75 32.3 -8.53 5.83
Incyte INCY 119.65 19.4 1.66 23.9
Juno Therapeut JUNO 22.4 18.6 -9.9 2.33
Kite Pharma KITE 86.7 93.29 22 5.25
Loxo Oncology LOXO 75.8 135.65 72.25 2.03
Merck MRK 63.2 7.42 -1.27 171.2
Novartis NVS 81 11.27 4.04 211.65
Puma Biotech PBYI 80.95 163.2 178 2.89
Roche ADR RHHBY 31.87 11.74 -5.53 220.84
Seattle Genet SGEN 64.76 22.6 7.28 9.15
TESARO TSRO 139.45 3.86 2.05 70
iShares IBB 294.8 11 1.83 8.05
SPDR S&P XBI 71.6 21 4.94 3.15

BLUE, BMY, RHHBY, XBI are in the Rayno Biopharma Portfolio.

, , , , , , ,

No comments yet.

Leave a Reply